PHS
LLY icon

PFM Health Sciences’s Eli Lilly LLY Stock Holding History

PFM Health Sciences’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39,700
Closed -$13.6M – 89
2023
Q1 		$13.6M Buy
+39,700
New +$13.4M 0.6% 55
2016
Q4 		– Sell
-486,200
Closed -$39M – 110
2016
Q3 		$39M Buy
+486,200
New +$38.9M 1.14% 33

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PFM Health Sciences's LLY Position: Q2 2026 in Review

PFM Health Sciences reduced its Eli Lilly (LLY) stake by 40% in Q2 2026, selling an estimated $27.1M and leaving 39,258 shares worth $47.1M. The position accounts for 4.04% of the portfolio, ranked #3.

PFM Health Sciences first reported a position in LLY in Q3 2015 and has held it in 25 quarters since. The position peaked at $270M in Q2 2024. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • PFM Health Sciences held 39,258 shares of Eli Lilly worth $47.1M as of Q2 2026.
  • PFM Health Sciences sold 26,504 Eli Lilly shares in Q2 2026, an estimated $27.1M.
  • Eli Lilly made up 4.04% of PFM Health Sciences's portfolio in Q2 2026, its #3 holding.
  • PFM Health Sciences first reported a position in Eli Lilly in Q3 2015 and has held it in 25 quarters since.
  • PFM Health Sciences's Eli Lilly position peaked at $270M in Q2 2024.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.